Product Portfolio

Featured Products

Our product portfolio features several leading products, including Rasuvo®, Metoject®, RUPALLTM, Gliolan®, and Treosulfan. Through our business development strategy, we are also actively licensing and/or acquiring new products to supplement our growing pipeline.


Rasuvo is a once-weekly, subcutaneous, single-dose auto-injector of methotrexate indicated for the treatment of rheumatoid arthritis, psoriasis and juvenile idiopathic arthritis (JIA).

Learn About Rasuvo


IXINITY® [coagulation factor IX (recombinant)] is a medicine used to replace clotting factor (factor IX) that is missing in adults and children at least 12 years of age with hemophilia B.  

Learn About Ixinity®


Metoject is a pre-filled syringe of methotrexate indicated for the treatment of rheumatoid arthritis and psoriasis

Learn About Metoject


Rupall is indicated for the treatment of Seasonal Allergic Rhinitis (SAR), Perennial Allergic Rhinitis (PER) and Chronic Spontaneous Urticaria (CSU) in patients 2 years of age and older.

Learn About Rupall™


Gliolan is an orally administered drug used for the visualization of certain brain tumors.



Treosulfan is a conditioning agent used prior to stem cell transplantation.

Portfolio by Growth Phase

Portfolio by Growth Phase

*Percentages are of the Company’s revenue as disclosed in the condensed interim consolidated statements of loss and comprehensive income (unaudited) of the Company for the nine-month period ended December 31, 2019, as filed on SEDAR, plus the pro-forma impact of Ixinity, as if the acquisition had been completed at the beginning of the fiscal year.

Two Robust Divisions

Two Robust Divisions

Our strong North American commercial platform is supported by our operations via our two divisions: Medexus Pharma Canada and Medexus Pharma USA.

View Divisions